179 related articles for article (PubMed ID: 22526864)
1. β2-adrenergic receptor haplotype may be associated with susceptibility to desensitization to long-acting β2-agonists in COPD patients.
Mochizuki H; Nanjo Y; Kawate E; Yamazaki M; Tsuda Y; Takahashi H
Lung; 2012 Aug; 190(4):411-7. PubMed ID: 22526864
[TBL] [Abstract][Full Text] [Related]
2. Better adherence to a transdermal tulobuterol patch than inhaled salmeterol in elderly chronic obstructive pulmonary disease patients.
Mochizuki H; Nanjo Y; Takahashi H
Geriatr Gerontol Int; 2013 Apr; 13(2):398-404. PubMed ID: 22817699
[TBL] [Abstract][Full Text] [Related]
3. Comparison of bronchodilatory properties of transdermal and inhaled long-acting beta 2-agonists.
Yamagata T; Hirano T; Sugiura H; Yanagisawa S; Ichikawa T; Ueshima K; Akamatsu K; Nakanishi M; Matsunaga K; Minakata Y; Ichinose M
Pulm Pharmacol Ther; 2008; 21(1):160-5. PubMed ID: 17632023
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy and safety of transdermal tulobuterol in the treatment of stable COPD: an open-label comparison with inhaled salmeterol.
Fukuchi Y; Nagai A; Seyama K; Nishimura M; Hirata K; Kubo K; Ichinose M; Aizawa H;
Treat Respir Med; 2005; 4(6):447-55. PubMed ID: 16336029
[TBL] [Abstract][Full Text] [Related]
5. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease.
Farne HA; Cates CJ
Cochrane Database Syst Rev; 2015 Oct; (10):CD008989. PubMed ID: 26490945
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of dual therapy with GSK233705 and salmeterol versus monotherapy with salmeterol, tiotropium, or placebo in a crossover pilot study in partially reversible COPD patients.
Beier J; van Noord J; Deans A; Brooks J; Maden C; Baggen S; Mehta R; Cahn A
Int J Chron Obstruct Pulmon Dis; 2012; 7():153-64. PubMed ID: 22419863
[TBL] [Abstract][Full Text] [Related]
7. Lung function response to 12-week treatment with combined inhalation of long-acting beta2 agonist and glucocorticoid according to ADRB2 polymorphism in patients with chronic obstructive pulmonary disease.
Kim WJ; Oh YM; Sung J; Kim TH; Huh JW; Jung H; Lee JH; Kim EK; Lee JH; Lee SM; Lee S; Lim SY; Shin TR; Yoon HI; Kwon SY; Lee SD
Lung; 2008; 186(6):381-6. PubMed ID: 18758858
[TBL] [Abstract][Full Text] [Related]
8. Arrhythmias in patients with chronic obstructive pulmonary disease (COPD): occurrence frequency and the effect of treatment with the inhaled long-acting beta2-agonists arformoterol and salmeterol.
Hanrahan JP; Grogan DR; Baumgartner RA; Wilson A; Cheng H; Zimetbaum PJ; Morganroth J
Medicine (Baltimore); 2008 Nov; 87(6):319-328. PubMed ID: 19011503
[TBL] [Abstract][Full Text] [Related]
9. Inhaled long-acting β2 agonists enhance glucocorticoid receptor nuclear translocation and efficacy in sputum macrophages in COPD.
Haque R; Hakim A; Moodley T; Torrego A; Essilfie-Quaye S; Jazrawi E; Johnson M; Barnes PJ; Adcock IM; Usmani OS
J Allergy Clin Immunol; 2013 Nov; 132(5):1166-73. PubMed ID: 24070494
[TBL] [Abstract][Full Text] [Related]
10. Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease.
Spencer S; Evans DJ; Karner C; Cates CJ
Cochrane Database Syst Rev; 2011 Oct; (10):CD007033. PubMed ID: 21975759
[TBL] [Abstract][Full Text] [Related]
11. Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial.
Wechsler ME; Kunselman SJ; Chinchilli VM; Bleecker E; Boushey HA; Calhoun WJ; Ameredes BT; Castro M; Craig TJ; Denlinger L; Fahy JV; Jarjour N; Kazani S; Kim S; Kraft M; Lazarus SC; Lemanske RF; Markezich A; Martin RJ; Permaul P; Peters SP; Ramsdell J; Sorkness CA; Sutherland ER; Szefler SJ; Walter MJ; Wasserman SI; Israel E;
Lancet; 2009 Nov; 374(9703):1754-64. PubMed ID: 19932356
[TBL] [Abstract][Full Text] [Related]
12. Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease.
Welsh EJ; Cates CJ; Poole P
Cochrane Database Syst Rev; 2013 May; (5):CD007891. PubMed ID: 23728670
[TBL] [Abstract][Full Text] [Related]
13. Beta2-adrenergic receptor genetic polymorphisms and short-term bronchodilator responses in patients with COPD.
Hizawa N; Makita H; Nasuhara Y; Betsuyaku T; Itoh Y; Nagai K; Hasegawa M; Nishimura M
Chest; 2007 Nov; 132(5):1485-92. PubMed ID: 17890463
[TBL] [Abstract][Full Text] [Related]
14. Comparison of dry powder versus nebulized beta-agonist in patients with COPD who have suboptimal peak inspiratory flow rate.
Mahler DA; Waterman LA; Ward J; Gifford AH
J Aerosol Med Pulm Drug Deliv; 2014 Apr; 27(2):103-9. PubMed ID: 23745526
[TBL] [Abstract][Full Text] [Related]
15. Differential desensitization of homozygous haplotypes of the beta2-adrenergic receptor in lymphocytes.
Oostendorp J; Postma DS; Volders H; Jongepier H; Kauffman HF; Boezen HM; Meyers DA; Bleecker ER; Nelemans SA; Zaagsma J; Meurs H
Am J Respir Crit Care Med; 2005 Aug; 172(3):322-8. PubMed ID: 15879418
[TBL] [Abstract][Full Text] [Related]
16. Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study.
Larsson K; Janson C; Lisspers K; Jørgensen L; Stratelis G; Telg G; Ställberg B; Johansson G
J Intern Med; 2013 Jun; 273(6):584-94. PubMed ID: 23495860
[TBL] [Abstract][Full Text] [Related]
17. Long-acting beta2-agonists for chronic obstructive pulmonary disease.
Appleton S; Smith B; Veale A; Bara A
Cochrane Database Syst Rev; 2000; (2):CD001104. PubMed ID: 10796594
[TBL] [Abstract][Full Text] [Related]
18. Comparison of adherence and efficacy between inhaled salmeterol and transdermal tulobuterol patch in elderly patients with chronic obstructive pulmonary disorder.
Sugawara T; Nanjo Y; Yamazaki M; Higashihara K; Tsuda Y; Mochizuki H; Noguchi T; Takahashi H
J Am Geriatr Soc; 2009 May; 57(5):919-20. PubMed ID: 19470012
[No Abstract] [Full Text] [Related]
19. Role of Long-Acting Muscarinic Antagonist/Long-Acting β
Petite SE
Ann Pharmacother; 2017 Aug; 51(8):696-705. PubMed ID: 28410560
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacological action and clinical aspects of salmeterol].
Oguri K
Nihon Yakurigaku Zasshi; 2003 Sep; 122(3):265-70. PubMed ID: 12939544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
